ImmuCell reports Q2 2026 results, presses ahead with capacity expansion
The animal health company posted second-quarter net income of $1.8 million as it moves through a multi-phase plan to expand First Defense production.
SEC filing
Latest
2 stories
Thursday, August 13
Thursday, July 9
ImmuCell reports 11.5% Q2 2026 sales growth, driven by domestic demand
The animal health company posted preliminary second-quarter sales of $7.2 million, with domestic growth offsetting a decline in international sales.
SEC filing